Amphotericin-B in dermatology

Agarwal, Akash; Kar, BikashR

doi:10.4103/idoj.idoj_573_21

Cited by 2 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LipAmphB can be nebulized without disrupting liposomes, thus allowing AmphB to directly reach the lung [86]. Topical formulations of both AmphB and LipAmphB have been also created for the treatment of skin fungal infections or cutaneous leishmaniasis [89,90]. However, the therapeutic effects of these formulations are a matter of discussion considering both the type of infection and the clinical study.…”

Section: Amphotericin B and Lipid Raft Disruption As Therapeutical Ap...mentioning

confidence: 99%

Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox

Peruzzu

Fecchi

Venturi

et al. 2023

IJMS

View full text Add to dashboard Cite

Mpox (monkeypox) is a zoonotic viral disease caused by the mpox virus (MPXV). Recently in 2022, a multi-country Mpox outbreak has determined great concern as the disease rapidly spreads. The majority of cases are being noticed in European regions and are unrelated to endemic travel or known contact with infected individuals. In this outbreak, close sexual contact appears to be important for MPXV transmission, and an increasing prevalence in people with multiple sexual partners and in men who have sex with men has been observed. Although Vaccinia virus (VACV)-based vaccines have been shown to induce a cross-reactive and protective immune response against MPXV, limited data support their efficacy against the 2022 Mpox outbreak. Furthermore, there are no specific antiviral drugs for Mpox. Host-cell lipid rafts are small, highly dynamic plasma-membrane microdomains enriched in cholesterol, glycosphingolipids and phospholipids that have emerged as crucial surface-entry platforms for several viruses. We previously demonstrated that the antifungal drug Amphotericin B (AmphB) inhibits fungal, bacterial and viral infection of host cells through its capacity to sequester host-cell cholesterol and disrupt lipid raft architecture. In this context, we discuss the hypothesis that AmphB could inhibit MPXV infection of host cells through disruption of lipid rafts and eventually through redistribution of receptors/co-receptors mediating virus entry, thus representing an alternative or additional therapeutic tool for human Mpox.

show abstract

Section: Amphotericin B and Lipid Raft Disruption As Therapeutical Ap...mentioning

confidence: 99%